Third Harmonic Bio (THRD, Financial) has announced that its shareholders have largely endorsed the company's Plan of Liquidation and Dissolution during the Annual Meeting held on June 5, 2025. Alongside this, the company shared the outcomes of an additional cohort from its Phase 1 trial for its oral wild-type KIT inhibitor, THB335, and has started the process of selling this candidate as part of the dissolution strategy.
Pending final approval from the Board of Directors, Third Harmonic Bio anticipates executing the dissolution and beginning initial payouts to shareholders in the third quarter of 2025. The plan received support from 99.9% of voting shareholders, accounting for 83.7% of the company’s total outstanding common shares. Current estimates suggest that stockholders might receive distributions ranging from $5.30 to $5.44 per share, with the first installment expected to be between $5.30 and $5.35 per share.
These figures exclude potential funds from asset sales, including THB335, which could affect the final distribution sums. As such, actual payouts may significantly differ from the company's estimates due to varying factors.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Third Harmonic Bio Inc (THRD, Financial) is $4.25 with a high estimate of $5.50 and a low estimate of $3.00. The average target implies an downside of 19.20% from the current price of $5.26. More detailed estimate data can be found on the Third Harmonic Bio Inc (THRD) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Third Harmonic Bio Inc's (THRD, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
